THERMO FISHER SCIENTIFIC INC.
TMOAPI behind this page
TMO Q2 2025 request
Playground key active
/api/financials?ticker=TMO&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 10,855 | 10,541 | +3.0% |
Show Product Lines breakouts |
|||
| Consumables | 4,606 | 4,363 | +5.6% |
| Instruments | 1,644 | 1,800 | -8.7% |
| Product | 6,249 | 6,163 | +1.4% |
| Service | 4,605 | 4,378 | +5.2% |
Show Business Segments breakouts |
|||
| Analytical Instruments | 1,669 | 1,727 | -3.4% |
| Analytical Instruments · Chemical analysis | 292 | 324 | -9.9% |
| Analytical Instruments · Chromatography and mass spectrometry | 784 | 773 | +1.4% |
| Analytical Instruments · Electron microscopy | 652 | 684 | -4.7% |
| Analytical Instruments · Material Reconciling Items | 58 | 55 | +5.5% |
| Analytical Instruments · Operating Segments | 1,728 | 1,782 | -3.0% |
| Laboratory Products and Biopharma Services | 5,953 | 5,719 | +4.1% |
| Laboratory Products and Biopharma Services · Clinical research | 1,955 | 1,949 | +0.3% |
| Laboratory Products and Biopharma Services · Intersegment Elimination | -238 | -233 | -2.1% |
| Laboratory Products and Biopharma Services · Laboratory products | 601 | 639 | -5.9% |
| Laboratory Products and Biopharma Services · Material Reconciling Items | 42 | 39 | +7.7% |
| Laboratory Products and Biopharma Services · Operating Segments | 5,995 | 5,758 | +4.1% |
| Laboratory Products and Biopharma Services · Pharma services | 1,794 | 1,627 | +10.3% |
| Laboratory Products and Biopharma Services · Research and safety market channel | 1,883 | 1,775 | +6.1% |
| Life Sciences Solutions | 2,115 | 1,996 | +6.0% |
| Life Sciences Solutions · BioProduction | 745 | 633 | +17.7% |
| Life Sciences Solutions · Biosciences | 1,075 | 1,059 | +1.5% |
| Life Sciences Solutions · Genetic sciences | 679 | 663 | +2.4% |
| Life Sciences Solutions · Material Reconciling Items | 385 | 359 | +7.2% |
| Life Sciences Solutions · Operating Segments | 2,499 | 2,355 | +6.1% |
| Specialty Diagnostics | 1,118 | 1,100 | +1.6% |
| Specialty Diagnostics · Clinical diagnostics | 276 | 273 | +1.1% |
| Specialty Diagnostics · Healthcare market channel | 407 | 411 | -1.0% |
| Specialty Diagnostics · ImmunoDiagnostics | 234 | 226 | +3.5% |
| Specialty Diagnostics · Intersegment Elimination | -65 | -62 | -4.8% |
| Specialty Diagnostics · Material Reconciling Items | 16 | 17 | -5.9% |
| Specialty Diagnostics · Microbiology | 159 | 158 | +0.6% |
| Specialty Diagnostics · Operating Segments | 1,134 | 1,117 | +1.5% |
| Specialty Diagnostics · Transplant diagnostics | 124 | 111 | +11.7% |
Show Geography breakouts |
|||
| Asia Pacific | 1,920 | 1,971 | -2.6% |
| Europe | 2,830 | 2,663 | +6.3% |
| North America | 5,722 | 5,529 | +3.5% |
| Other regions | 383 | 379 | +1.1% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -501 | -470 | -6.6% |
| Material Reconciling Items | 501 | 470 | +6.6% |
| Operating Segments | 11,356 | 11,011 | +3.1% |
| Cost of Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 3,239 | 3,080 | +5.2% |
| Service | 3,207 | 3,114 | +3.0% |
| Selling, General & Administrative | 2,140 | 2,111 | +1.4% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 318 | 305 | +4.3% |
| Laboratory Products and Biopharma Services · Operating Segments | 599 | 596 | +0.5% |
| Life Sciences Solutions · Operating Segments | 467 | 428 | +9.1% |
| Specialty Diagnostics · Operating Segments | 183 | 188 | -2.7% |
| Research & Development | 352 | 339 | +3.8% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 145 | 139 | +4.3% |
| Laboratory Products and Biopharma Services · Operating Segments | 14 | 17 | -17.6% |
| Life Sciences Solutions · Operating Segments | 136 | 130 | +4.6% |
| Specialty Diagnostics · Operating Segments | 47 | 44 | +6.8% |
| Restructuring And Other Costs Income Net | 82 | 77 | +6.5% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 10 | — | — |
| Laboratory Products and Biopharma Services · Operating Segments | 56 | — | — |
| Life Sciences Solutions · Operating Segments | 11 | — | — |
| Specialty Diagnostics · Operating Segments | 3 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 2 | — | — |
| Material Reconciling Items | 82 | 77 | +6.5% |
| Total Costs & Expenses | 9,021 | 8,722 | +3.4% |
| Operating Income | 1,834 | 1,820 | +0.8% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 325 | 439 | -26.0% |
| Laboratory Products and Biopharma Services · Operating Segments | 825 | 745 | +10.7% |
| Life Sciences Solutions · Operating Segments | 919 | 865 | +6.2% |
| Specialty Diagnostics · Operating Segments | 306 | 299 | +2.3% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,375 | 2,347 | +1.2% |
| Interest Income | 297 | 295 | +0.7% |
| Interest Expense | -404 | -354 | -14.1% |
| Other Non-Operating Income (Expense) | -19 | 5 | -480.0% |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | 1,709 | 1,765 | -3.2% |
| Income Tax Expense (Benefit) | -92 | -128 | +28.1% |
| Income Loss From Equity Method Investments | 2 | -84 | +102.4% |
| Net Income | 1,618 | 1,553 | +4.2% |
| Net Income Loss Attributable To Noncontrolling Interest | 2 | 6 | -66.7% |
| Net Income | 1,617 | 1,548 | +4.5% |
| EPS (Basic) | 4.28 | 4.05 | +5.7% |
| EPS (Diluted) | 4.28 | 4.04 | +5.9% |
| Wtd Avg Shares (Basic) | 378 | 382 | -1.0% |
| Wtd Avg Shares (Diluted) | 378 | 383 | -1.3% |
| Cost of Revenue (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 902 | 852 | +5.9% |
| Laboratory Products and Biopharma Services · Operating Segments | 4,683 | 4,504 | +4.0% |
| Life Sciences Solutions · Operating Segments | 925 | 860 | +7.6% |
| Specialty Diagnostics · Operating Segments | 640 | 623 | +2.7% |
| Comprehensive Income | 1,164 | 1,899 | -38.7% |
| Gain Loss On Investments | -3 | — | — |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 4,576 | — | — |
| Short-Term Investments | 1,814 | 1,750 | +3.7% |
| Accounts Receivable | 8,594 | 7,943 | +8.2% |
| Inventory | 5,559 | — | — |
| Contract With Customer Asset Net Current | 1,441 | — | — |
| Other Assets Current | 2,599 | 2,025 | +28.3% |
| Total Current Assets | 24,584 | 25,476 | -3.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 9,635 | 9,282 | +3.8% |
| Other Non-Current Assets | 4,615 | 4,377 | +5.4% |
| Goodwill | 47,249 | — | — |
| Total Assets | 101,230 | 98,496 | +2.8% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 3,070 | 2,723 | +12.7% |
| Laboratory Products and Biopharma Services · Operating Segments | 6,711 | 6,314 | +6.3% |
| Life Sciences Solutions · Operating Segments | 3,142 | 3,025 | +3.9% |
| Specialty Diagnostics · Operating Segments | 1,295 | 1,188 | +9.0% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 87,013 | 85,247 | +2.1% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 15,148 | 15,519 | -2.4% |
| Current Liabilities | |||
| Debt Current | 2,214 | 5,121 | -56.8% |
| Accounts Payable | 2,980 | 2,547 | +17.0% |
| Employee Related Liabilities Current | 1,518 | 1,495 | +1.5% |
| Deferred Revenue (Current) | 2,805 | — | — |
| Other Liabilities Current | 3,200 | 3,019 | +6.0% |
| Total Current Liabilities | 12,718 | 14,772 | -13.9% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 624 | 1,516 | -58.8% |
| Other Non-Current Liabilities | 4,270 | 4,391 | -2.8% |
| Long-Term Debt | 35,033 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Other | 1 | — | — |
| Senior Notes | 35,031 | — | — |
| Contract With Customer Liability Noncurrent | 1,122 | — | — |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 33,015 | 30,284 | +9.0% |
| Redeemable Noncontrolling Interest Equity Carrying Amount | 126 | 115 | +9.6% |
| Stockholders' Equity | |||
| Common Stock | 444 | 443 | +0.2% |
| Additional Paid In Capital Common Stock | 18,232 | 17,649 | +3.3% |
| Retained Earnings | 55,901 | 49,940 | +11.9% |
| Treasury Stock Common Value | -21,269 | -18,187 | -16.9% |
| Accumulated Other Comprehensive Income | -2,797 | -2,413 | -15.9% |
| Total Stockholders' Equity | 50,512 | 47,432 | +6.5% |
| Minority Interest | -35 | -12 | -191.7% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 50,476 | 47,419 | +6.4% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -270 | — | — |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -24 | — | — |
| Accumulated Other Comprehensive Income | -2,797 | -2,413 | -15.9% |
| Accumulated Translation Adjustment | -2,502 | — | — |
| Additional Paid In Capital | 18,232 | 17,649 | +3.3% |
| Common Stock | 444 | 443 | +0.2% |
| Noncontrolling Interest | -35 | -12 | -191.7% |
| Parent | 50,512 | 47,432 | +6.5% |
| Retained Earnings | 55,901 | 49,940 | +11.9% |
| Treasury Stock Common | -21,269 | -18,187 | -16.9% |
| Total Liabilities & Equity | 101,230 | 98,496 | +2.8% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 532 | 562 | -5.3% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 50 | 50 | 0.0% |
| Laboratory Products and Biopharma Services · Operating Segments | 324 | 356 | -9.0% |
| Life Sciences Solutions · Operating Segments | 114 | 112 | +1.8% |
| Specialty Diagnostics · Operating Segments | 44 | 44 | 0.0% |
| Amortization Of Intangible Assets | 859 | 1,065 | -19.3% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 859 | 1,065 | -19.3% |
| Deferred Income Taxes | -601 | -607 | +1.0% |
| Stock-Based Compensation | 156 | 154 | +1.3% |
| Other Non-Cash Items | 198 | 157 | +26.1% |
| Increase Decrease In Operating Capital Excluding Deferred Taxes | -2,151 | -1,003 | -114.5% |
| Net Cash from Operations | 2,122 | 3,211 | -33.9% |
| Investing Activities | |||
| Capital Expenditures | -656 | -648 | -1.2% |
| Proceeds From Sale Of Property Plant And Equipment | 13 | 20 | -35.0% |
| Proceeds From Payments For Cross Currency Interest Rate Swap Interest Settlements | 134 | 111 | +20.7% |
| Payments To Acquire Investments | -311 | -1,778 | +82.5% |
| Other Investing Activities | 6 | 12 | -50.0% |
| Net Cash from Investing | -815 | -2,283 | +64.3% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 2,840 | 1,204 | +135.9% |
| Repayments Of Long Term Debt | -1,625 | — | — |
| Share Repurchases | -2,000 | -3,000 | +33.3% |
| Payments Of Dividends Common Stock | -311 | -284 | -9.5% |
| Proceeds From Payments For Other Financing Activities | 3 | 145 | -97.9% |
| Net Cash from Financing | -1,093 | -1,936 | +43.5% |
| Supplemental | |||
| Unpaid Capital Expenditures | 206 | 166 | +24.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 348 | 7 | +4871.4% |
| Net Change in Cash | 563 | -1,000 | +156.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4,603 | 7,097 | -35.1% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.